The UCLA Biomarker Reference Laboratory (UCLA BRL) is designed to be a continuation and expansion of the established EDRN-funded UCLA BRL. Significantly, the UCLA BRL has been highly successful having established numerous EDRN collaborations and constructed and successfully utilized tissue microarray resources for EDRN investigators. Our goals are in close alignment with the mission of the EDRN and include: i) the utilization of our diverse and extensive infrastructure and highly skilled personnel to test, evaluate, quantify, validate and optimize detection of biomarkers useful early stage tumor marker. To this end, we have established Scientific Centers that can test for biomarkers which are protein and/or nucleic acid in nature in tissue and/or in fluids. To this end, the Scientific Centers have extensive experience and expertise in assay performance and development for tissues (full tissue sections or 'intelligent high-density tissue microarrays), proteins (including conventional and high-throughput protemics), and nucleic acids (including expression profiles, DNA modifications or mutations, chromosomal abnormalities, and/or microRNA profiles), ii) This includes a developmental program focused on defining clinically useful tumor markers utilizing high density tissue microarray combined with a novel data-mining tool suite, iii) The continuation of a program at UCLA that is highly professional and focused, yet at the same time flexible and cost-effective in order to meet the challenges of an evolving EDRN program, iv) A strong commitment to collaboration, teamwork, and sharing of resources and data with EDRN members in order to promote the goal of identifying clinically useful tumor biomarkers. The UCLA BRL leadership is highly capable and enthusiastic, and strongly dedicated to the goals of the EDRN. Moreover, the UCLA-BRL has strong institutional support from the School of Medicine, Jonsson Comprehensive Cancer Center, the UCLA Lung Cancer Program, and the UCLA Prostate Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA086366-13
Application #
8296107
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (M2))
Program Officer
Sorbara, Lynn R
Project Start
2000-05-16
Project End
2015-06-30
Budget Start
2012-08-06
Budget End
2013-06-30
Support Year
13
Fiscal Year
2012
Total Cost
$379,129
Indirect Cost
$133,570
Name
University of California Los Angeles
Department
Pathology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Qin, Yu; Fu, Maoyong; Takahashi, Masamichi et al. (2014) Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. J Biol Chem 289:13974-85
Ho, Melissa E; Quek, Sue-Ing; True, Lawrence D et al. (2013) Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Mod Pathol 26:849-59
Gordon, L K; Kiyohara, M; Fu, M et al. (2013) EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene 32:5369-76
Huynh, Thu P; Mah, Vei; Sampson, Valerie B et al. (2012) Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol Lung Cell Mol Physiol 302:L1150-8
Huerta-Yepez, Sara; Yoon, Nam K; Hernandez-Cueto, Angeles et al. (2011) Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer 11:259
Rao, Rajiv G; Sudhakar, Deepthi; Hogue, Claire P et al. (2011) Peripheral myelin protein-22 (PMP22) modulates alpha 6 integrin expression in the human endometrium. Reprod Biol Endocrinol 9:56
Marquez-Garban, Diana C; Mah, Vei; Alavi, Mohammad et al. (2011) Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids 76:910-20
Mao, Jenny T; Roth, Michael D; Fishbein, Michael C et al. (2011) Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4:984-93
Diamandis, Eleftherios P; Goodglick, Lee; Planque, Chris et al. (2011) Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 17:2395-9

Showing the most recent 10 out of 32 publications